Every material Form 8-K Xtant Medical Holdings, Inc. has filed with the SEC since April 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Xtant Medical reported a second-quarter 2026 net loss of $9.4 million, compared with net income of $3.6 million a year earlier, as revenue fell to $23.0 million from $35.4 million. The company also lowered its full-year 2026 revenue guidance to $99 million to $103 million from $101 million to $105 million, citing lower-than-expected biologics revenue and amnio product headwinds.
Q2 2026 total revenue was $23.0 million versus $35.4 million in Q2 2025; gross margin was 57.9% versus 68.6%.
Q2 2026 net loss was $9.4 million; non-GAAP adjusted EBITDA loss was $2.7 million versus positive $6.9 million a year earlier.
Full-year 2026 revenue guidance was cut to $99 million to $103 million from $101 million to $105 million.
A $5.0 million exclusivity fee paid to Dilon Technologies for a U.S. distribution agreement was written off in the quarter; cash was $9.9 million as of June 30, 2026.
Xtant Medical reported first-quarter 2026 revenue of $20.9 million, down from $32.9 million a year earlier, and a net loss of $3.1 million, compared with net income of $58,000. The company raised its full-year 2026 revenue guidance to $101 million to $105 million from $95 million to $99 million, citing its exclusive U.S. distribution agreement for Dilon Technologies' HEMOBLAST Bellows product. Revenue and profit declined while guidance rose, so the results point in mixed directions for shareholders.
Q1 2026 revenue was $20.9 million versus $32.9 million in Q1 2025, mainly due to the Companion Spine asset sale and 2025 license revenue that did not repeat.
Q1 2026 net loss was $3.1 million versus net income of $58,000; non-GAAP adjusted EBITDA was a loss of $1.6 million versus positive $3.0 million.
2026 revenue guidance raised to $101 million to $105 million from $95 million to $99 million, tied to the Dilon Technologies HEMOBLAST Bellows agreement.
Total indebtedness fell $13.3 million in Q1 2026; cash and cash equivalents were $12.2 million as of March 31, 2026.
Xtant Medical entered a distribution agreement dated April 10, 2026 with Dilon Technologies, giving Xtant exclusive U.S. rights to import, market, distribute and sell the FDA-approved HEMOBLAST Bellows hemostatic powder. Xtant also hired about 20 Dilon sales personnel and plans to update its full-year 2026 guidance with its first quarter 2026 results, so shareholders will see the financial effect when that guidance is released.
Xtant paid Dilon a $5.0 million exclusivity fee, which Dilon may have to repay in certain circumstances, including termination of the agreement.
Xtant hired approximately 20 Dilon sales personnel to sell the product in the United States.
Dilon will continue to manufacture HEMOBLAST Bellows in France and sell it to Xtant at a transfer price that can change under the agreement.
The agreement has no minimum purchase requirements for Xtant; Xtant plans to update 2026 guidance with its Q1 2026 results.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Xtant Medical Holdings, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →